Cyclopharm (ASX:CYC)
ASX announcement history & article coverage
Transparent by design.
Announcments by Cyclopharm (ASX:CYC) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Cyclopharm 1H 2026 Results Webinar
CYC 1H2026 Results Summary
Cyclopharm reports record 1H2026 revenue of A$17.5m driven by 74% US growth and new US guidelines
Half Yearly Report and Accounts
Cyclopharm reports record half-year revenue driven by US growth; net loss widens amid investment
New US Lung Imaging Guidelines Name Technegas as Preferred A
New US Lung Imaging Guidelines Name Technegas® as Preferred Ventilation Agent
ausbiz TV Presentation
Immediate 11-Site Technegas Rollout at University Hospitals
Cyclopharm Signs 11-Site Technegas® Agreement with University Hospitals Cleveland
Notification of cessation of securities - CYC
CYC First-Half 2026 Update
Cyclopharm reports record half-year revenue, US installation guidance deferred after clinical guideline approval delay
Change in substantial holding